Trials / Completed
CompletedNCT00453401
Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis
The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,000 (estimated)
- Sponsor
- NanoBio Corporation · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NB-001 |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-03-28
- Last updated
- 2008-05-30
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00453401. Inclusion in this directory is not an endorsement.